Literature DB >> 19752779

Sphinganine-1-phosphate attenuates both hepatic and renal injury induced by hepatic ischemia and reperfusion in mice.

Sang Won Park1, Mihwa Kim, Sean W C Chen, Vivette D D'Agati, H Thomas Lee.   

Abstract

Hepatic ischemia/reperfusion (I/R) injury is a major complication after liver transplantation, major hepatic resection, or prolonged portal vein occlusion. Furthermore, acute kidney injury is frequent after hepatic I/R and greatly increases postoperative complications. Sphinganine-1-phosphate is a sphingolipid with uncharacterized physiological effects. We serendipitously determined that plasma levels of sphinganine-1-phosphate fell significantly after liver I/R in mice. In this study, we hypothesized that repletion of plasma sphinganine-1-phosphate would protect against liver and kidney injuries after liver I/R. C57BL/6 mice were subjected to 60 min of partial hepatic I/R and treated with either vehicle or with sphinganine-1-phosphate (given immediately before and 2 h after reperfusion). Vehicle-treated mice subjected to liver I/R developed acute liver and kidney injuries with elevated plasma alanine aminotransferase and creatinine 5 and 24 h after liver I/R. However, liver and kidney injuries were significantly attenuated with sphinganine-1-phosphate treatment. Sphinganine-1-phosphate markedly inhibited liver and kidney necrosis and apoptosis 24 h after liver I/R. Moreover, sphinganine-1-phosphate attenuated neutrophil infiltration, reduced plasma IL-6 and TNF-alpha upregulation, and preserved liver and kidney vascular integrity while reducing liver and kidney F-actin degradation after liver I/R. Finally, sphinganine-1-phosphate-mediated hepatic and renal protection was blocked by VPC23019, an antagonist for sphingosine-1-phosphate type 1 receptor. Therefore, sphinganine-1-phosphate improves acute liver and kidney injuries after hepatic I/R via sphingosine-1-phosphate type 1 receptor-mediated inhibition of necrosis and apoptosis and by improving vascular integrity. Harnessing the mechanisms of cytoprotection with sphinganine-1-phosphate activation may lead to new therapies for perioperative hepatic I/R injury and subsequent remote organ injury.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19752779      PMCID: PMC2794916          DOI: 10.1097/SHK.0b013e3181c02c1f

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  31 in total

Review 1.  Ischemia and reperfusion injury in liver transplantation.

Authors:  J W Kupiec-Weglinski; R W Busuttil
Journal:  Transplant Proc       Date:  2005-05       Impact factor: 1.066

Review 2.  Putting the actin cytoskeleton into perspective: pathophysiology of ischemic alterations.

Authors:  B A Molitoris
Journal:  Am J Physiol       Date:  1997-04

3.  Sphingosine 1-phosphate analogs as receptor antagonists.

Authors:  Michael D Davis; Jeremy J Clemens; Timothy L Macdonald; Kevin R Lynch
Journal:  J Biol Chem       Date:  2004-12-08       Impact factor: 5.157

4.  A rapid and simple method for the isolation of apoptotic DNA fragments.

Authors:  M Herrmann; H M Lorenz; R Voll; M Grünke; W Woith; J R Kalden
Journal:  Nucleic Acids Res       Date:  1994-12-11       Impact factor: 16.971

Review 5.  Sphingolipids--the enigmatic lipid class: biochemistry, physiology, and pathophysiology.

Authors:  A H Merrill; E M Schmelz; D L Dillehay; S Spiegel; J A Shayman; J J Schroeder; R T Riley; K A Voss; E Wang
Journal:  Toxicol Appl Pharmacol       Date:  1997-01       Impact factor: 4.219

6.  Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine.

Authors:  S Suzuki; L H Toledo-Pereyra; F J Rodriguez; D Cejalvo
Journal:  Transplantation       Date:  1993-06       Impact factor: 4.939

Review 7.  Generation and metabolism of bioactive sphingosine-1-phosphate.

Authors:  Hervé Le Stunff; Sheldon Milstien; Sarah Spiegel
Journal:  J Cell Biochem       Date:  2004-08-01       Impact factor: 4.429

8.  Pharmacological characterization of human S1P4 using a novel radioligand, [4,5-3H]-dihydrosphingosine-1-phosphate.

Authors:  James Fossetta; Gregory Deno; Waldemar Gonsiorek; Xuedong Fan; Brian Lavey; Pradip Das; Charles Lunn; Paul J Zavodny; Daniel Lundell; R William Hipkin
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

9.  Sphingosine: a mediator of acute renal tubular injury and subsequent cytoresistance.

Authors:  M Iwata; J Herrington; R A Zager
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

10.  Dual actions of sphingosine-1-phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival.

Authors:  J R Van Brocklyn; M J Lee; R Menzeleev; A Olivera; L Edsall; O Cuvillier; D M Thomas; P J Coopman; S Thangada; C H Liu; T Hla; S Spiegel
Journal:  J Cell Biol       Date:  1998-07-13       Impact factor: 10.539

View more
  23 in total

1.  Sphingosine kinase-2 inhibition improves mitochondrial function and survival after hepatic ischemia-reperfusion.

Authors:  Yanjun Shi; Hasibur Rehman; Venkat K Ramshesh; Justin Schwartz; Qinlong Liu; Yasodha Krishnasamy; Xun Zhang; John J Lemasters; Charles D Smith; Zhi Zhong
Journal:  J Hepatol       Date:  2011-07-12       Impact factor: 25.083

Review 2.  Sphingosine kinase and sphingosine-1-phosphate in liver pathobiology.

Authors:  Timothy Rohrbach; Michael Maceyka; Sarah Spiegel
Journal:  Crit Rev Biochem Mol Biol       Date:  2017-06-15       Impact factor: 8.250

3.  Naloxone pretreatment prevents kidney injury after liver ischemia reperfusion injury.

Authors:  Mohammad Ashrafzadeh Takhtfooladi; Mehran Shahzamani; Ahmad Asghari; Aris Fakouri
Journal:  Int Urol Nephrol       Date:  2016-04-07       Impact factor: 2.370

4.  Isoflurane post-conditioning protects against intestinal ischemia-reperfusion injury and multiorgan dysfunction via transforming growth factor-β1 generation.

Authors:  Minjae Kim; Sang Won Park; Mihwa Kim; Vivette D D'Agati; H Thomas Lee
Journal:  Ann Surg       Date:  2012-03       Impact factor: 12.969

Review 5.  The role of dihydrosphingolipids in disease.

Authors:  Ruth R Magaye; Feby Savira; Yue Hua; Darren J Kelly; Christopher Reid; Bernard Flynn; Danny Liew; Bing H Wang
Journal:  Cell Mol Life Sci       Date:  2018-12-06       Impact factor: 9.261

6.  Cytokines induce small intestine and liver injury after renal ischemia or nephrectomy.

Authors:  Sang Won Park; Sean W C Chen; Mihwa Kim; Kevin M Brown; Jay K Kolls; Vivette D D'Agati; H Thomas Lee
Journal:  Lab Invest       Date:  2010-08-09       Impact factor: 5.662

7.  IL-11 is required for A1 adenosine receptor-mediated protection against ischemic AKI.

Authors:  Joo Yun Kim; Mihwa Kim; Ahrom Ham; Kevin M Brown; Robert W Greene; Vivette D D'Agati; H Thomas Lee
Journal:  J Am Soc Nephrol       Date:  2013-06-27       Impact factor: 10.121

8.  Paneth cell-mediated multiorgan dysfunction after acute kidney injury.

Authors:  Sang Won Park; Mihwa Kim; Joo Yun Kim; Ahrom Ham; Kevin M Brown; Yuko Mori-Akiyama; André J Ouellette; Vivette D D'Agati; H Thomas Lee
Journal:  J Immunol       Date:  2012-10-29       Impact factor: 5.422

9.  Peptidyl arginine deiminase-4 activation exacerbates kidney ischemia-reperfusion injury.

Authors:  Ahrom Ham; May Rabadi; Mihwa Kim; Kevin M Brown; Zhe Ma; Vivette D'Agati; H Thomas Lee
Journal:  Am J Physiol Renal Physiol       Date:  2014-08-27

10.  Peptidyl arginine deiminase-4-deficient mice are protected against kidney and liver injury after renal ischemia and reperfusion.

Authors:  May Rabadi; Mihwa Kim; Vivette D'Agati; H Thomas Lee
Journal:  Am J Physiol Renal Physiol       Date:  2016-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.